Top Stories
If the biotech prices at the high end of its proposed range, its valuation could reach close to $1 billion.
Weltruza, the company's new formulation of olanzapine, needs no loading doses or oral supplementation.
TRex Bio is selling 8.3 million shares at $14 a piece for proceeds of around $117 million, while Retension Pharmaceuticals is selling about 3.8 million shares at $12 each, raising $45 million.
In RESTORE-3, Sycume significantly improved proptosis response rates versus placebo at week 24 in patients from China.
The biotech thinks taladegib (ENV-101), its Hedgehog signalling pathway inhibitor, can reverse the course of idiopathic pulmonary fibrosis (IPF).
Conference News
Linsitinib achieved a statistically significant proptosis responder rate of 52% vs. 19% for placebo at Week 24 (p=0.010)82% of Week 24 proptosis responders maintained their response through Week 72 (4...
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presen...
PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced that cli...
A BMJ review of 37 studies found weight returns within about two years, and faster after medication than after behavioral programs.SAN FRANCISCO, CA, UNITED STATES, October 9, 2026 /EINPresswire.com/ ...
Investigational therapy shows favorable safety profile; highest dose associated with greatest improvements in dry eye symptoms and corneal stainingMIAMI, FL, UNITED STATES, October 9, 2026 /EINPresswi...
